Inflammatory markers and stroke

Current Cardiology Reports

Volumn 11, Issue 1, 2009, Pages 12-20

  Elkind, Mitchell S V ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE;

BLOOD; HUMAN; LEUKOCYTE COUNT; METABOLISM; PATHOLOGY; REVIEW; STROKE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; STROKE;

EID: 63249087996     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-009-0003-2     Document Type: Article

References (52)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488. (Pubitemid 40923403)
3. Frostegard J, Ulfgren AK, Nyberg P, et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43. (Pubitemid 29292698)
4. Elkind MS, Cheng J, Boden-Albala B, et al.: Elevated white blood cell count and carotid plaque thickness: the Northern Manhattan Stroke Study. Stroke 2001, 32:842-849. (Pubitemid 32285146)
5. Elkind MS, Sciacca R, Boden-Albala B, et al.: Relative elevation in leukocyte count predicts first cerebral infarction. Neurology 2005, 64:2121-2125. (Pubitemid 40881005)
6. Sen S, Hinderliter A, Sen PK, et al.: Association of leukocyte count with progression of aortic atheroma in stroke/transient ischemic attack patients. Stroke 2007, 38:2900-2905. This study demonstrates that leukocyte count, a simple measure of inflammatory burden, is associated with progression of aortic atheroma, a potential risk factor for stroke. (Pubitemid 350035682)
7. Grau AJ, Boddy AW, Dukovic DA, et al.: Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004, 35:1147-1152. (Pubitemid 38543534)
8. Lange LA, Carlson CS, Hindorff LA, et al.: Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006, 296:2703-2711. This study provides evidence from a large epidemiologic study that genetic polymorphisms in genes related to important inflammation-related proteins are associated with atherosclerosis and clinical events. This provides an important direction for future research. (Pubitemid 44917547)
9. Di Napoli M, Schwaninger M, Cappelli R, et al.: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36:1316-1329. (Pubitemid 40798763)
10. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843. (Pubitemid 30165206)
11. Curb JD, Abbott RD, Rodriguez BL, et al.: C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003, 107:2016-2020. (Pubitemid 36506076)
12. Cao JJ, Thach C, Manolio TA, et al.: C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003, 108:166-170. (Pubitemid 36871298)
13. Verma S, Szmitko PE, Yeh ET: C-reactive protein. Structure affects function. Circulation 2004, 109:1914-1917. (Pubitemid 38544477)
14. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. (Pubitemid 36158056)
15. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611-619. An excellent and lucid study demonstrating the role of state-of-theart assessment of risk, using a combination of clinical historical factors and biomarkers, including hsCRP, to determine future risk of cardiovascular events among women. The study reports the latest clinical epidemiologic methods and uses global vascular risk as an outcome, rather than more limited outcomes related to heart disease only.
16. Woodward M, Lowe GD, Campbell DJ, et al.: Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005, 36:2143-2147. (Pubitemid 41429235)
17. Welsh P, Lowe GD, Chalmers J, et al.: Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008, 39:2226-2230. A clever use of an existing database and stored blood samples from a stroke clinical trial to answer questions about the value of multiple inflammatory biomarkers in stroke patients.
18. Arenillas JF, Alvarez-Sabín J, Molina CA, et al.: Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke 2008, 39:1456-1463. One of the major strengths of this study is its focus on a particular etiologic subtype of stroke, intracranial atherosclerosis. This is an important advance because stroke, unlike heart disease, is heterogeneous and many stroke studies do not distinguish among stroke subtypes.
19. Montaner J, Fernandez-Cadenas I, Molina CA, et al.: Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006, 37:1205-1210. (Pubitemid 43731863)
20. Cho AH, Kim JS, Jeon SB, et al.: Mechanism of multiple infarcts in multiple cerebral circulations on diffusionweighted imaging. J Neurol 2007, 254:924-930. (Pubitemid 47222293)
21. Oei HH, Van Der Meer IM, Hofman A, et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575. (Pubitemid 40216483)
22. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479-2484. (Pubitemid 41720009)
23. Elkind MS, Tai W, Coates K, et al.: Lipoprotein-associated phospholipase A2, C-reactive protein, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073-2080. A population-based study in a multiethnic cohort demonstrating the relative values of hsCRP and Lp-PLA2 as prognostic factors after stroke. hsCRP appeared to be a better predictor of mortality and Lp-PLA2 a better predictor of recurrent vascular events. (Pubitemid 44631394)
24. Elkind MS, Tai W, Coates K, et al.: Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2008 (in press).
25. Nadareishvili ZG, Li H, Wright V, et al.: Elevated proinflammatory CD4+CD28-lymphocytes and stroke recurrence and death. Neurology 2004, 63:1446-1451. (Pubitemid 39426279)
26. Garlichs CD, Kozina S, Fateh-Moghadam S, et al.: Upregulation of CD40-CD40 Ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412-1418.
27. Schumacher H, Kaiser E, Schnabel PA, et al.: Immunophenotypic characterisation of carotid plaque: increased amount of inflammatory cells as an independent predictor for ischaemic symptoms. Eur J Vasc Endovasc Surg 2001, 21:494-501. (Pubitemid 32624582)
28. Ding S, Zhang M, Zhao Y, et al.: The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci 2008, 336:27-31.
29. Prabhakaran S, Rundek T, Ramas R, et al.: Carotid plaque surface irregularity predicts ischemic stroke: the Northern Manhattan Study. Stroke 2006, 37 2696-2701. (Pubitemid 44922528)
30. Corrado E, Rizzo M, Tantillo R, et al.: Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006, 37:482-486. In this large study using multimodal biomarker analysis, including infectious and inflammatory serum biomarkers and Doppler, inflammatory biomarkers predicted stoke risk in patients with asymptomatic carotid stenosis. This provides supportive evidence that inflammation may be used to distinguish low- and high-risk carotid patients. This provides an important direction for new research, and if confirmed, these findings could lead to new approaches to risk stratification in such patients. (Pubitemid 43732010)
31. Schillinger M, Exner M, Mlekusch W, et al.: Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation 2005, 111:2203-2209. (Pubitemid 40632436)
32. Gröschel K, Ernemann U, Larsen J, et al.: Preprocedural C-reactive protein levels predict stroke and death in patients undergoing carotid stenting. AJNR Am J Neuroradiol 2007, 28:1743-1746. (Pubitemid 47598152)
33. Krupinski J, Turu MM, Font MA, et al.: Blood-borne tissue factor activity predicts major cerebrovascular events in patients undergoing carotid endarterectomy: results from a 1-year follow-up study. Cerebrovasc Dis 2008, 25:32-39. (Pubitemid 351280373)
34. Weiss CR, Arai AE, Bui MN, et al.: Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans. J Magn Reson Imaging 2001, 14:698-704 (Pubitemid 33101528)
35. Corti R, Fuster V, Fayad ZA, et al.: Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005, 46:106-112. (Pubitemid 40905137)
36. Van Dijk EJ, Prins ND, Vermeer SE, et al.: C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005, 112:900-905. (Pubitemid 41170078)
37. Fornage M, Chiang A, O'Meara ES, et al.: Biomarkers of inflammation and MRI-defined small vessel disease of the brain. The Cardiovascular Health Study. Stroke 2008, 39:1952-1959. An important analysis of the relationship between inflammatory biomarkers and small-vessel disease supporting the notion that inflammation plays a role in small-vessel disease.
38. Jefferson AL, Massaro JM, Wolf PA, et al.: Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007, 68:1032-1038. Another important analysis from the Framingham population demonstrating that inflammatory biomarkers are also associated with brain atrophy. (Pubitemid 46569138)
39. Revilla M, Obach V, Cervera A, et al.: A-174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett 2002, 324:29-32. (Pubitemid 34442670)
40. Castellanos M, Castillo J, Garcia MM, et al.: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002, 33:982-987. (Pubitemid 34293579)
41. Smeeth L, Thomas SL, Hall AJ, et al.: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618. (Pubitemid 39628582)
42. Grau AJ, Fischer B, Barth C, et al.: Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005, 36:1501-1506. (Pubitemid 40967520)
43. Nagel MA, Cohrs RJ, Mahalingam R, et al.: The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008, 70:853-860. An excellent case series, including cases from many centers, of varicella zoster virus (VZV)-associated vasculopathy, a rare disease that provides an example of how infection may lead to cerebrovascular injury and stroke. The investigators also determined that anti-VZV antibodies may be a better diagnostic tool than polymerase chain reaction. (Pubitemid 351367506)
44. Davis MM, Taubert K, Benin AL, et al.: Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation 2006, 114:1549-1553. This guideline from two major cardiology societies recommends using influenza vaccination to prevent recurrent cardiovascular events among patients with existent cardiovascular disease. This represents the first anti-infective strategy widely used to prevent vascular disease. Stroke patients were not explicitly included in the guidelines, but it may be reasonable to extrapolate these recommendations to stroke patients as well. (Pubitemid 44527011)
45. Zeller JA, Lenz A, Eschenfelder CC, et al.: Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol 2005, 25:1519-1523. (Pubitemid 40923378)
46. Herzberg MC, Nobbs A, Tao L, et al.: Oral streptococci and cardiovascular disease: searching for the platelet aggregation-associated protein gene and mechanisms of Streptococcus sanguis-induced thrombosis. J Periodontol 2005, 76(11 Suppl):2101-2105. (Pubitemid 41748959)
47. Elkind MS, Sciacca R, Boden-Albala B, et al.: Leukocyte count is associated with reduced endothelial reactivity. Atherosclerosis 2005, 181:329-338. (Pubitemid 41019614)
48. Charakida M, Donald AE, Terese M, et al.: Endothelial dysfunction in childhood infection. Circulation 2005, 111:1660-1665. (Pubitemid 40525166)
49. Pleiner J, Schaller G, Mittermayer F, et al.: Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004, 110:3349-3354. (Pubitemid 39557498)
50. Elkind MS: Implications of stroke prevention trials: treatment of global risk. Neurology 2005, 65:17-21. (Pubitemid 40967770)
51. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28. (Pubitemid 40075677)
52. Kinlay S, Schwartz GG, Olsson AG, et al.: Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 2008, 28:142-147. This is the first study to demonstrate that inflammatory biomarkers, such as hsCRP, may be useful measures of the efficacy of statins in stroke prevention. It shows what other trials, such as PROVE-IT, have shown for hsCRP and Lp-PLA2 in cardiac disease.